



## Editorial

Welcome to a new chapter in the evolution of the *European Journal of Cancer*. The New Year brings some new editors, and a new look to the Journal! As the new Editor-in-Chief, I would like to start by paying tribute to my predecessor, Hans-Jorg Senn, whose wisdom, experience and hard work have contributed very significantly to the development of the *European Journal of Cancer*. Medical publishing is highly competitive, and during my stewardship of the Journal, I shall do everything I can to further develop the Journal, aiming to realise the full potential of a truly *European* journal. I shall be greatly helped in this by our two new editors — Jaap Verweij and Maurizio D'Incalci, complementing the strengths of the existing team. Ian Hart is stepping down as Editor for Experimental Oncology, and in thanking him for all that he has done so far, we hope that he will continue to advise and support us. Brad Timms, our Administrative Editor, is leaving the Journal, and his efficiency, tolerance and sense of humour will be greatly missed. We welcome Mandy Kelly to the journal as his replacement.

European cancer medicine is advancing rapidly as a result of excellence in research and an expansion in the provision of healthcare in many, but not all, our member countries. Such improvements are, however, challenged by an increasingly well informed public, whose expectations of cancer prevention, screening and treatment, increase year on year. The more we have to offer, the greater the resource needed — an essential fact that is not always welcomed by the politicians, whose responsibility it is to apportion expenditure for health.

The issues are far from straightforward, and progress needs intelligent debate between researchers, doctors and the professions allied to medicine (who are increasingly involved in healthcare delivery), government agencies, industry and the elected politicians.

Our mission for the *European Journal of Cancer* is primarily to publish the best possible papers, and for that we invite you all to submit your most important work. The Editorial Board and our publisher will seek to be fair and fast in getting results into print. In addition to this research element, however, we wish to encourage greater awareness of political issues that affect all of the Societies and organisations for whom we are the official journal, and indeed all those involved in European cancer medicine. We shall do this through the News section, anchored by Helen Saul. We hope to extend the network of sources for news gathering and welcome input from any and all sources to Helen at [h.saul@elsevier.co.uk](mailto:h.saul@elsevier.co.uk). Factual information is particularly welcome, but “allowable” gossip can also provide excellent reading!

On behalf of all my editorial board, we wish you a very happy, healthy and literary New Year.

John Smyth  
Editor-in-Chief  
*ICRF Medical Oncology Unit, MRC Building*  
*Western General Hospital, Crewe Road*  
*Edinburgh EH4 2XU, UK*  
*E-mail address: [smyth@icrf.icnet.uk](mailto:smyth@icrf.icnet.uk)*